The journal of nutrition, health & aging

, Volume 14, Issue 9, pp 770–774 | Cite as

Memantine benefits functional abilities in moderate to severe Alzheimer’s disease

  • Bengt Winblad
  • S. Gauthier
  • D. Åström
  • K. Stender
Memantine Benefits Functional Abilities in Moderate to Severe Alzheimer’s Disease



Functional abilities are severely impacted in Alzheimer’s disease (AD). Loss of the ability to perform complex (instrumental) and basic activities of daily living (ADL), leads to decreased independence and increased caregiver burden. This post-hoc analysis investigated the effect of memantine (20 mg/day) on ADLs, as measured by Alzheimer’s Disease Cooperative Study-Activities of Daily Living 19-item (ADCSADL19) and 23-item (ADCS-ADL23) scales, in patients with moderate-to-severe AD.


Data were pooled from six multicenter, randomized, placebo-controlled, double-blind, 6-month studies of memantine 20 mg/day.


Male and female patients aged ≥50 years at baseline with a Mini Mental State Examination (MMSE) score <20.


ADCS-ADL19 and ADCS-ADL23 scales were pooled, and 14 shared items, with a score range of 0–45, were identified and included in the analysis (ADL14). Basic ADLs (BADLs) were defined as: eating, walking, toileting, bathing, and grooming. Instrumental ADLs (IADLs) were defined as: using a telephone, watching television, conversing, clearing a table, finding belongings, obtaining a beverage, disposing of household rubbish, travelling outside the house, and being left alone. Changes from baseline on single-item, BADL (range: 0–15), IADL (range: 0–30), and total ADL14 scores were analysed for observed cases using ANCOVA, with study, center and treatment as categorical explanatory variables and score at baseline as a covariate.


959 patients were treated with memantine and 867 patients received placebo. Memantine-treated patients had less decline from baseline on the ADL14 total score, compared with placebo (p<0.001) at study end. Memantine also showed lower reductions in BADLs (p<0.05) and IADLs (p<0.001), for observed cases, compared with placebo. Memantine-treated patients showed less worsening than placebo recipients for the ADL items: toileting (p<0.01), grooming (p<0.01), finding belongings (p<0.01), and travelling outside the house (p<0.05).


Compared with placebo, memantine shows benefits for both basic and instrumental ADLs in patients with moderate-to-severe AD, suggesting that memantine treatment may lead to a more interactive and dignified life for patients with moderate-to-severe AD.

Key words

Memantine Alzheimer’s disease functional ability 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351:56–67.CrossRefPubMedGoogle Scholar
  2. 2.
    Galasko D, Schmitt F, Thomas R, Jin S, Bennett D. Detailed assessment of activities of daily living in moderate to severe Alzheimer’s disease. J Int Neuropsychol Soc. 2005;11:446–453.PubMedGoogle Scholar
  3. 3.
    Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(Suppl 5):S4–S9.PubMedGoogle Scholar
  4. 4.
    Smith GE, O’Brien PC, Ivnik RJ, Kokmen E, Tangalos EG. Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology. 2001;57:1467–1473.PubMedGoogle Scholar
  5. 5.
    Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287:2090–2097.CrossRefPubMedGoogle Scholar
  6. 6.
    Georges J, Jansen S, Jackson J, Meyrieux A, Sadowska A, Selmes M. Alzheimer’s disease in real life-the dementia carer’s survey. Int J Geriatr Psychiatry. 2008;23:546–551.CrossRefPubMedGoogle Scholar
  7. 7.
    Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18,(Suppl 1):S23–S32.CrossRefPubMedGoogle Scholar
  8. 8.
    Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J Alzheimers Dis. 2004;6(Suppl):S61–S74.PubMedGoogle Scholar
  9. 9.
    Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31:577–585.CrossRefPubMedGoogle Scholar
  10. 10.
    Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23:537–545.CrossRefPubMedGoogle Scholar
  11. 11.
    Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24:20–27.CrossRefPubMedGoogle Scholar
  12. 12.
    Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24:532–538.CrossRefPubMedGoogle Scholar
  13. 13.
    Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135–146.CrossRefPubMedGoogle Scholar
  14. 14.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69:459–469.CrossRefPubMedGoogle Scholar
  15. 15.
    Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord. 2009;27:232–239.CrossRefPubMedGoogle Scholar
  16. 16.
    Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman L, Wetterholm A-L, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet, 2006:367:1057–1065CrossRefPubMedGoogle Scholar
  17. 17.
    Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2007;11:471–479.PubMedGoogle Scholar
  18. 18.
    Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14:704–715.CrossRefPubMedGoogle Scholar
  19. 19.
    Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341.CrossRefPubMedGoogle Scholar
  20. 20.
    Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–324.CrossRefPubMedGoogle Scholar
  21. 21.
    van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21:136–143.CrossRefPubMedGoogle Scholar
  22. 22.
    Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83–89.CrossRefPubMedGoogle Scholar
  23. 23.
    Criteria for the clinical diagnosis of Alzheimer’s disease. Excerpts from the NINCDS-ADRDA Work Group report. J Am Geriatr Soc. 1985;33:2–3.Google Scholar
  24. 24.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944.PubMedGoogle Scholar
  25. 25.
    Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22:209–221.CrossRefPubMedGoogle Scholar
  26. 26.
    Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer’s disease. Drugs. 2006;66:1515–1534.CrossRefPubMedGoogle Scholar
  27. 27.
    Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics. 2003;21:327–340.CrossRefPubMedGoogle Scholar
  28. 28.
    Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Memantine enhances autonomy in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19:458–464.CrossRefPubMedGoogle Scholar
  29. 29.
    Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:600–607.CrossRefPubMedGoogle Scholar

Copyright information

© Serdi and Springer Verlag France 2010

Authors and Affiliations

  • Bengt Winblad
    • 1
    • 4
  • S. Gauthier
    • 2
  • D. Åström
    • 3
  • K. Stender
    • 3
  1. 1.Karolinska InstitutetAlzheimer Disease Research Center (KI-ADRC) NOVUMHuddingeSweden
  2. 2.McGill Center for Studies in AgingDouglas Institute for Mental HealthMontrealCanada
  3. 3.H. Lundbeck A/SCopenhagenDenmark
  4. 4.Karolinska InstitutetAlzheimer Disease Research Center (KI-ADRC) NOVUMHuddingeSweden

Personalised recommendations